Trial record 1 of 1 for:
ASPEN03
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04675294 |
|
Recruitment Status :
Recruiting
First Posted : December 19, 2020
Last Update Posted : March 22, 2024
|
Sponsor:
ALX Oncology Inc.
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
ALX Oncology Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 31, 2024 |
| Estimated Study Completion Date : | December 31, 2025 |